EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

RNAemia and Severe Coronavirus Disease 2019: Candidate Treatment Targets Identified Through Transcriptomics

Sultanah Alharthi iD, Nusrat J Epsi, David A Lindholm iD, Pavol Genzor, Milissa Jones, Heba H Mostafa, Anuradha Ganesan, Rupal Mody iD, Katrin Mende, Manish Bhomia iD, Carlos Maldonado, Timothy Burgess iD und 10 weitere

The Journal of Infectious Diseases · 29.07.2026

DOI: 10.1093/infdis/jiag390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 29.07.2026. Verfasst von Sultanah Alharthi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, Nashville, TN, USA. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Defense Health Program, National Institute of Allergy and Infectious Disease, Infectious Disease Clinical Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in blood has been proposed as a marker of severe coronavirus disease 2019 (COVID-19), but it is unclear whether RNAemia mediates the pathway toward worsening disease. We hypothesized that RNAemia is associated with severe disease and distinct gene expression patterns are associated with RNAemia and severe COVID-19. These RNAemia-associated patterns may identify COVID-19 treatment targets.

Methods

We analyzed 202 hospitalized COVID-19 participants from a multicenter US Military Health System cohort using digital droplet polymerase chain reaction to quantify SARS-CoV-2 RNA in plasma and performed host RNA sequencing of peripheral blood. Differential gene expression logistic regression models were used to assess associations among RNAemia, host gene expression, and disease severity.

Results

RNAemia was detected in 39.1% of participants and was associated with severe disease (54% vs 32% in RNAemia-negative participants; P < .001). In final adjusted models, independent predictors of severity included RNAemia (adjusted odds ratio [aOR] range 1.99–2.24, all P ≤ .04), as well as host genes ADAMTS2 (aOR = 1.58, P < .001), OLAH (aOR = 1.55, P < .001), and PCSK9 (aOR = 1.60, P < .001).

Conclusions

RNAemia is an independent predictor of COVID-19 severity. However, host gene expression changes associated with RNAemia, particularly involving OLAH, PCSK9, and ADAMTS2, had stronger statistical evidence of severe outcomes than RNAemia itself. PCSK9 is an intervenable treatment target worth further study.

Schlagwörter

Stichwörter der Autor:innen

BiomarkersCOVID-19Disease severityHost responseRNA sequencingRNAemiaSARS-CoV-2Transcriptomics

Autor:innen und Institutionen

  • Vanderbilt University Medical Center, Nashville, TN, USA.
  • Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
  • Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
  • Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
  • Brooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, TX, USA.
  • Department of Pediatrics, Uniformed Services University, Bethesda, MD, USA.

ORCID-Profile: Sultanah Alharthi, David A Lindholm, Rupal Mody, Manish Bhomia, Timothy Burgess, David Tribble, Brian K Agan, John S Dumler, Paul W Blair

Förderung

  • Defense Health Program
  • National Institute of Allergy and Infectious Disease
  • Infectious Disease Clinical Research Program
  • IDCRP
  • Department of War
  • Uniformed Services University of the Health Sciences
  • Henry M. Jackson Foundation
  • Advancement of Military Medicine, Inc

Zitieren

APA

Alharthi, S., Epsi, N. J., Lindholm, D. A., Genzor, P., Jones, M., Mostafa, H. H., Ganesan, A., Mody, R., Mende, K., Bhomia, M., Maldonado, C., Burgess, T., Tribble, D., Simons, M. P., Colombo, R. E., Richard, S. A., Agan, B. K., Dalgard, C. L., Dumler, J. S., …, & EPICC research group (2026). RNAemia and Severe Coronavirus Disease 2019: Candidate Treatment Targets Identified Through Transcriptomics. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag390

Vancouver

Alharthi S, Epsi NJ, Lindholm DA, Genzor P, Jones M, Mostafa HH, et al. RNAemia and Severe Coronavirus Disease 2019: Candidate Treatment Targets Identified Through Transcriptomics. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag390

BibTeX
@article{Alharthi2026,
  author = {Alharthi, Sultanah and Epsi, Nusrat J and Lindholm, David A and Genzor, Pavol and Jones, Milissa and Mostafa, Heba H and Ganesan, Anuradha and Mody, Rupal and Mende, Katrin and Bhomia, Manish and Maldonado, Carlos and Burgess, Timothy and Tribble, David and Simons, Mark P and Colombo, Rhonda E and Richard, Stephanie A and Agan, Brian K and Dalgard, Clifton L and Dumler, John S and Pollett, Simon D and Blair, Paul W and EPICC research group, EPICC research group},
  title = {RNAemia and Severe Coronavirus Disease 2019: Candidate Treatment Targets Identified Through Transcriptomics},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag390}
}
Kostenlos starten →